Study S001813

A Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3841136 Monotherapy, and LY3841136 in Combination With Tirzepatide, in Japanese Participants With Obesity or Overweight

ClinicalTrials.gov record

Registration

Registration: NCT06297616
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: DOUBLE
Status: COMPLETED
Enrollment: 128
Start: 2024-04-15
Primary completion: 2025-11-21
Lead sponsor: Eli Lilly and Company
Conditions: Obesity; Overweight
Interventions: DRUG:LY3841136; DRUG:LY3841136-Placebo; DRUG:Tirzepatide; DRUG:Tirzepatide-Placebo
Results posted: FALSE
Individual participant data sharing: NO
Secondary identifiers: OTHER:J3R-JE-YDAB

Registered primary outcomes

Part A: Number of Participants with One or More Serious Adverse Events (SAE) Considered by the Investigator to be Related to Study Drug Administration at Week 22 [Baseline through Week 22]
Part B: Number of Participants with One or More Serious Adverse Events (SAE) Considered by the Investigator to be Related to Study Drug Administration at Week 34 [Baseline through Week 34]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.